PlainRecalls
FDA Drug Moderate Class II Terminated

Orphenadrine Citrate Extended-Release Tablets, USP 100 mg, Rx Only, 100 Tablets, Manufactured by Sandoz Inc., Princeton, NJ 08540 NDC 0185-0022-01.

Reported: April 13, 2022 Initiated: March 21, 2022 #D-0753-2022

Product Description

Orphenadrine Citrate Extended-Release Tablets, USP 100 mg, Rx Only, 100 Tablets, Manufactured by Sandoz Inc., Princeton, NJ 08540 NDC 0185-0022-01.

Reason for Recall

CGMP Deviations:Nitrosamine impurity (NMOA) above the acceptable daily limit.

Details

Recalling Firm
Sandoz, Inc
Units Affected
7908 bottles(790,800 extended release tablets)
Distribution
Nationwide
Location
Princeton, NJ

Frequently Asked Questions

What product was recalled?
Orphenadrine Citrate Extended-Release Tablets, USP 100 mg, Rx Only, 100 Tablets, Manufactured by Sandoz Inc., Princeton, NJ 08540 NDC 0185-0022-01.. Recalled by Sandoz, Inc. Units affected: 7908 bottles(790,800 extended release tablets).
Why was this product recalled?
CGMP Deviations:Nitrosamine impurity (NMOA) above the acceptable daily limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 13, 2022. Severity: Moderate. Recall number: D-0753-2022.